COVID-19 @ NIBIB

NIBIB's goal is to accelerate research, translation, and commercialization of technologies that will provide solutions to the COVID-19 pandemic.

NIBIB is administering the RADx℠ Tech and Advanced Technology Platforms (ATP) programs. These programs are part of the NIH RADx℠ Initiative to increase testing capacity and accessibility for SARS-CoV-2, the virus that causes COVID. In addition, NIBIB is supporting other technology development, imaging approaches, and digital platforms to address the pandemic.

Rapid Acceleration of Diagnostics (RADx℠) Tech and ATP Programs

The RADx Tech and ATP programs are supporting late-stage development of innovative point-of-care, home-based tests, and clinical laboratory tests.

Summary data on proposals submitted to the RADx℠ Tech and ATP Programs.

Descriptions of innovative point of care, home-based, improved clinical laboratory tests, and testing products that are increasing the capacity of testing in the U.S.

COVID-19 Research across NIBIB

NIBIB’s Dr. Kaitlyn Sadtler is a study lead and Principal Investigator working with NIH colleagues to test people who were infected with SARS-CoV-2 and developed antibodies but did not develop symptoms. Read about results from this study.

Learn how this collaborative network is using medical imaging and clinical data sciences to reveal unique features of COVID-19. Learn more about this resource.

Videos

View videos about RADx Tech/ATP programs, interviews with the NIBIB Director and more.

Program Contacts

RADxSM Tech/ATP programmatic or technical inquiries: info.radx@poctrn.org

All other RADxSM Tech/ATP Applicants: RADxNIBIB@mail.nih.gov

SBIR/STTR Applicants: NIBIB-SBIR@mail.nih.gov

All others: COVID19NIBIB@nibib.gov

Related News

July 1, 2021
Rapid antigen coronavirus tests are just as accurate as laboratory tests when used every three days, a new study from the National Institutes of Health (NIH) finds. Source: Daily Mail
July 1, 2021
A small study funded by NIH has found that COVID-19 antigen testing and PCR tests are equally effective in detecting SARS-CoV-2 infection when used for serial screening conducted every three days. The results are good news for antigen test makers such as Abbott, Becton Dickinson and Quidel. Source: Medtechdive
June 30, 2021
Amid the continued deluge of emergency use authorizations from the FDA, rapid antigen tests for COVID-19 are more widely available and easily accessible than ever. Source: FierceBiotech
June 30, 2021
holding a test sample
In a study that compares rapid antigen and laboratory PCR approaches for COVID-19 serial screening, researchers affiliated with the NIH RADx initiative reported results from 43 people infected with the virus.
June 22, 2021
pipetting
NIH researchers report that the prevalence of COVID-19 in the United States during spring and summer of 2020 far exceeded the known number of cases. For every diagnosed COVID-19 case in this time frame, the researchers estimate that there were 4.8 undiagnosed cases, representing an additional 16.8 million cases by July alone.